Literature DB >> 24602919

Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial.

Ming Kai Lam1, Kenneth Tandjung, Hanim Sen, Mounir W Z Basalus, K Gert van Houwelingen, Martin G Stoel, Johannes W Louwerenburg, Gerard C M Linssen, Salah A M Saïd, Mark B Nienhuis, Frits H A F de Man, Job van der Palen, Clemens von Birgelen.   

Abstract

AIMS: To investigate the prognostic value of coronary dominance for various adverse clinical events following the implantation of drug-eluting stents. METHODS AND
RESULTS: We assessed two-year follow-up data of 1,387 patients from the randomised TWENTE trial. Based on the origin of the posterior descending coronary artery, coronary circulation was categorised into left and non-left dominance (i.e., right and balanced). Target vessel-related myocardial infarction (MI) was defined according to the updated Academic Research Consortium (ARC) definition (2x upper reference limit of creatine kinase [CK], confirmed by CK-MB elevation), and periprocedural MI (PMI) as MI ≤48 hours following PCI. One hundred and thirty-six patients (9.8%) had left and 1,251 (90.2%) non-left dominance. Target lesions were more frequently located in dominant arteries (p<0.005). Left dominance was associated with more severe calcifications (p=0.006) and more bifurcation lesions (p=0.031). Non-left dominance tended to be less frequent in men (p=0.09). Left coronary dominance was associated with more target vessel-related MI (14 [10.3%] vs. 62 [5.0%], p=0.009). Left dominance independently predicted PMI (adjusted HR 2.19, 95% CI: 1.15-4.15, p=0.017), while no difference in other clinical endpoints was observed between dominance groups.
CONCLUSIONS: In the population of the TWENTE trial, we observed a higher incidence of periprocedural myocardial infarction in patients who had left coronary dominance.

Entities:  

Mesh:

Year:  2015        PMID: 24602919     DOI: 10.4244/EIJV11I2A32

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  6 in total

1.  The essential role for endothelial cell sprouting in coronary collateral growth.

Authors:  Anurag Jamaiyar; Cody Juguilon; Weiguo Wan; Devan Richardson; Sofia Chinchilla; James Gadd; Molly Enrick; Tao Wang; Caige McCabe; Yang Wang; Chris Kolz; Alyssa Clark; Sathwika Thodeti; Vahagn Ohanyan; Feng Dong; Bin Zhou; William Chilian; Liya Yin
Journal:  J Mol Cell Cardiol       Date:  2022-01-22       Impact factor: 5.000

2.  Significance of inferior wall ischemia in non-dominant right coronary artery anatomy.

Authors:  Ali Osama Malik; Oliver Abela; Subodh Devabhaktuni; Arhama Aftab Malik; Gayle Allenback; Chowdhury H Ahsan; Sanjay Malhotra; Jimmy Diep
Journal:  World J Cardiol       Date:  2017-03-26

3.  Association of coronary dominance with the severity of coronary artery disease: a cross-sectional study in Shaanxi Province, China.

Authors:  Bin Yan; Jian Yang; Yajuan Fan; Binbin Zhao; Qingyan Ma; Lihong Yang; Xiancang Ma
Journal:  BMJ Open       Date:  2018-11-08       Impact factor: 2.692

4.  Association between coronary dominance and acute inferior myocardial infarction: a matched, case-control study.

Authors:  Li Wang; Jiamei Li; Ya Gao; Ruohan Li; Jingjing Zhang; Dan Su; Tao Wang; Guang Yang; Xiaochuang Wang
Journal:  BMC Cardiovasc Disord       Date:  2019-02-04       Impact factor: 2.298

5.  Association of coronary artery dominance and mortality rate and complications in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Amir Mikaeilvand; Ata Firuozi; Hosseinali Basiri; Aida Varghaei; Peyman Izadpanah; Javad Kojuri; Alireza Abdi-Ardekani; Armin Attar
Journal:  J Res Med Sci       Date:  2020-11-26       Impact factor: 1.852

6.  Prognostic Value of Coronary Dominance in Patients Undergoing Elective Coronary Artery Bypass Surgery.

Authors:  Emre Selcuk; Deniz Cevirme; Onursal Bugra
Journal:  Braz J Cardiovasc Surg       Date:  2020-08-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.